Jonathan Kaufman MD
Overview
Board certified in medical oncology, Dr. Kaufman's practice includes treating multiple myeloma and amyloidosis patients at Emory University Hospital. As the Medical Director and Section Chief of the Winship Cancer Institute Ambulatory Infusion Centers, Dr. Kaufman coordinates the care for over 10,000 cancer patients served each year. He started practicing with Emory Healthcare as a network physician in 2005. He is also an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant.
Dr. Kaufman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He also holds memberships with American Society of Clinical Oncology and American Society of Hematology.
Dr. Kaufman earned his Medical Degree from the Medical College of Georgia in Augusta. He subsequently completed his Residency in Internal Medicine and his Fellowship in Hematology and Oncology at Emory University.
Dr. Kaufman's research focus is on the development of optimal treatment regimens and new drug development for patients with plasma cell disorders.
His work has been published in journals such as New England Journal of Medicine, Journal of Clinical Oncology, Science Signaling, Blood, Leukemia, Clinical Cancer Research, Journal of Immunology, Cancer, and Clinical Lymphoma and Myeloma. He has presented his clinical research on multiple myeloma at invited institutional lectures, as well as national and international hematology and oncology conferences.
Academic Appointment
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Medical College of Georgia
- BS from University of Florida
Research
Focus
- My primary areas of research include (1) new drug development for relapsed multiple myeloma patients, (2) identification of induction therapy for these patients, (3) new therapies for Amyloidosis and (4) novel conditioning regimens for myeloma transplant patients.
Publications
-
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA CD3 bispecific antibody.
Leukemia Volume: 39 Page(s): 1545
06/01/2025 Authors: Raab MS; Cohen YC; Schjesvold F; Aardalen K; Oka A; Spencer A; Wermke M; Souza AD; Kaufman JL; Cafro AM -
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma.
Blood Adv Volume: 9 Page(s): 2438 - 2442
05/27/2025 Authors: Potdar SV; Kapadia S; Azeem MI; Radzievski R; Lakhani K; Joseph NS; Kaufman JL; Hofmeister CC; Gupta VA; Lonial S -
BCL2 inhibition for multiple myeloma and AL amyloidosis.
Br J Haematol Volume: 206 Page(s): 1285 - 1296
05/01/2025 Authors: Cani L; Gupta VA; Kaufman JL -
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes.
Clin Lymphoma Myeloma Leuk
04/11/2025 Authors: Varga C; Robinson M; Gupta V; Hofmeister CC; Nooka AK; Kaufman JL; Dhodapkar MV; Lonial S; Borden S; Ferreri C -
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged 65 years from GRIFFIN and PERSEUS.
Clin Lymphoma Myeloma Leuk
04/11/2025 Authors: Rodriguez-Otero P; Voorhees PM; Boccadoro M; Laubach J; Einsele H; Sborov DW; Dimopoulos MA; Broijl A; Mina R; Spencer A -
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract.
Clin Lymphoma Myeloma Leuk
04/08/2025 Authors: Scott SA; Roberts DL; Gupta VA; Joseph NS; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK; Kaufman JL -
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.
Blood Volume: 145 Page(s): 944 - 955
02/27/2025 Authors: Vogl DT; Atrash S; Holstein SA; Nadeem O; Benson D; Chaudry M; Biran N; Suryanarayan K; Li C; Liu Y -
Solvitur ambulando.
Blood Volume: 145 Page(s): 4 - 5
01/02/2025 Authors: Kaufman JL -
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Future Oncol Volume: 21 Page(s): 25 - 49
01/01/2025 Authors: Voorhees PM; Sborov DW; Laubach J; Kaufman JL; Reeves B; Rodriguez C; Silbermann R; Costa LJ; Anderson LD; Nathwani N -
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients.
Invest New Drugs Volume: 42 Page(s): 635 - 643
12/01/2024 Authors: Badawi MA; Engelhardt B; Dobkowska E; Deng R; Kaufman JL; Menon R; Salem AH -
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.
Cancer Volume: 130 Page(s): 3785 - 3796
11/15/2024 Authors: Metts JL; Aye JM; Crane JN; Oberoi S; Balis FM; Bhatia S; Bona K; Carleton B; Dasgupta R; Dela Cruz FS -
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
NPJ Vaccines Volume: 9 Page(s): 201
10/27/2024 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC -
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.
Nat Cancer Volume: 5 Page(s): 1459 - 1464
10/01/2024 Authors: Richard S; Lesokhin AM; Paul B; Kaufman JL; Pianko M; Biran N; Vij R; Doxie DB; Azeem MI; Martillo M -
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
Blood Cancer J Volume: 14 Page(s): 159
09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S -
Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cells.
Nucleic Acids Res Volume: 52 Page(s): 7539 - 7555
07/22/2024 Authors: Cinar M; Martinez-Medina L; Puvvula PK; Arakelyan A; Vardarajan BN; Anthony N; Nagaraju GP; Park D; Feng L; Sheff F -
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Blood Cancer J Volume: 14 Page(s): 107
07/08/2024 Authors: Chari A; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Silbermann R; Costa LJ; Anderson LD; Nathwani N -
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol Volume: 99 Page(s): 1257 - 1268
07/01/2024 Authors: Silbermann R; Laubach J; Kaufman JL; Sborov DW; Reeves B; Rodriguez C; Chari A; Costa LJ; Anderson LD; Nathwani N -
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA.
Lancet Haematol Volume: 11 Page(s): e510 - e520
07/01/2024 Authors: Khan MK; Nasti TH; Qian JY; Kleber TJ; Switchenko JM; Kaufman JL; Nooka AJ; Dhodapkar MV; Buchwald ZS; Obiekwe D -
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol Volume: 204 Page(s): 2227 - 2232
06/01/2024 Authors: Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes TM; Holstein SA; Anderson LD; Badros A -
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol Volume: 25 Page(s): e205 - e216
05/01/2024 Authors: Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gllego Prez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H -
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood Cancer J Volume: 14 Page(s): 69
04/22/2024 Authors: Callander NS; Silbermann R; Kaufman JL; Godby KN; Laubach J; Schmidt TM; Sborov DW; Medvedova E; Reeves B; Dhakal B -
Glcksklee, the Quad, and High-Risk Myeloma.
J Clin Oncol Volume: 42 Page(s): 1 - 3
01/01/2024 Authors: Nooka AK; Kaufman JL; Lonial S -
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
Blood Cancer J Volume: 13 Page(s): 191
12/20/2023 Authors: Scott SA; Marin EM; Maples KT; Joseph NS; Hofmeister CC; Gupta VA; Dhodapkar MV; Kaufman JL; Lonial S; Nooka AK -
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
Oncologist Volume: 28 Page(s): 1055 - 1063
12/11/2023 Authors: Lalonde CS; Switchenko JM; Behera M; Bilen MA; Owonikoko TK; Kaufman JL; Nooka AK; Lewis CM; Hitron E; Collins H -
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol Volume: 10 Page(s): e825 - e837
10/01/2023 Authors: Voorhees PM; Sborov DW; Laubach J; Kaufman JL; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD -
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
Res Sq
09/21/2023 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC -
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
JCO Oncol Pract Volume: 19 Page(s): 793 - 798
09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK -
Incidence, risk factors and impact of supraventricular tachycardia (SVT) with high dose therapy melphalan among myeloma patients undergoing autologous stem cell transplant (HDT/ASCT)
Volume: 23 Page(s): S126 - S127
09/01/2023 Authors: Simon K; Joseph N; Mandawat A; Hofmeister C; Shanmugam M; Kaufman J; Graiser M; Wyman S; Adisa O; Rupji M -
Comparison of a battery powered device (OnControl) versus manual Jamshidi needle for bone marrow biopsy in adult patients with plasma cell disorders: a prospective randomized control trial (RCT)
Volume: 23 Page(s): S288 - S288
09/01/2023 Authors: Andrews J; Joseph N; Neely J; Hatcher A; Rosand C; Palmer A; Harrington M; Roberts D; Raine C; Pruitt R -
Maintenance therapy with carfilzomib, pomalidomide and dexamethasone (KPd) in high-risk myeloma patients (pts): a Phase 2 study with a safety run-in
Volume: 23 Page(s): S119 - S120
09/01/2023 Authors: Nooka A; Joseph N; Dhodapkar M; Hofmeister C; Gupta V; Andrews J; Gleason C; Burton BJ; Rupji M; McFadden I -
The changing landscape of peri-transplant adverse events with HDT/ASCT and the impact on long term outcomes for myeloma patients
Volume: 23 Page(s): S129 - S130
09/01/2023 Authors: Wyman S; Joseph N; Adisa O; Matich T; Behera M; Graiser M; Simon K; Rupji M; Kaufman J; Hofmeister C -
Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
Volume: 23 Page(s): S113 - S113
09/01/2023 Authors: Joseph N; Kaufman J; Lonial S; Hofmeister C; Dhodapkar M; Gupta V; DiCamillo S; Roberts D; Boise L; Nooka A -
Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study)
Volume: 23 Page(s): S125 - S126
09/01/2023 Authors: Silbermann R; Laubach J; Kaufman J; Sborov D; Reeves B; Rodriguez C; Chari A; Costa L; Anderson L; Nathwani N -
Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma
Volume: 23 Page(s): S188 - S189
09/01/2023 Authors: Kaufman J; Quach H; Baz R; Vangsted AJ; Ho S-J; Abildgaard N; Laubach J; Ribrag V; Gibbs S; Medvedova E -
Exposure-response analysis of venetoclax in combination with carfilzomib and dexamethasone in t(11;14)-positive relapsed/refractory multiple myeloma patients
Volume: 23 Page(s): S161 - S162
09/01/2023 Authors: Badawi M; Engelhardt B; Dobkowska E; Deng R; Kaufman J; Menon R; Salem AH -
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.
bioRxiv
08/22/2023 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC -
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
J Clin Invest Volume: 133
08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S -
Preclinical discovery and initial clinical data of WVT078, a BCMA CD3 bispecific antibody.
Leukemia Volume: 37 Page(s): 1349 - 1360
06/01/2023 Authors: Raab MS; Cohen YC; Schjesvold F; Aardalen K; Oka A; Spencer A; Wermke M; Souza AD; Kaufman JL; Cafro AM -
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
J Immunother Cancer Volume: 11
05/01/2023 Authors: Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S -
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Transplant Cell Ther Volume: 29 Page(s): 174.e1 - 174.e10
03/01/2023 Authors: Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C -
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
Blood Cancer Discov Volume: 4 Page(s): 106 - 117
03/01/2023 Authors: Azeem MI; Nooka AK; Shanmugasundaram U; Cheedarla N; Potdar S; Manalo RJ; Moreno A; Switchenko JM; Cheedarla S; Doxie DB -
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
Blood Cancer J Volume: 13 Page(s): 29
02/20/2023 Authors: Maples KT; Hall KH; Joseph NS; Hofmeister CC; Gupta V; Dhodapkar MV; Kaufman JL; Nooka AK; Lonial S -
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.
Leukemia Volume: 36 Page(s): 2917 - 2921
12/01/2022 Authors: Slade M; Martin TG; Nathwani N; Fiala MA; Rettig MP; Gao F; Deol A; Buadi FK; Kaufman JL; Hofmeister CC -
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol Volume: 18 Page(s): 4443 - 4456
12/01/2022 Authors: Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes T; Holstein SA; Anderson LD; Badros A -
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Br J Haematol Volume: 199 Page(s): 355 - 365
11/01/2022 Authors: Sborov DW; Baljevic M; Reeves B; Laubach J; Efebera YA; Rodriguez C; Costa LJ; Chari A; Silbermann R; Holstein SA -
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
J Clin Oncol Volume: 40 Page(s): 3057 - 3064
09/10/2022 Authors: Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S -
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
Blood Cancer J Volume: 12 Page(s): 115
08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT -
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med Volume: 387 Page(s): 132 - 147
07/14/2022 Authors: Richardson PG; Jacobus SJ; Weller EA; Hassoun H; Lonial S; Raje NS; Medvedova E; McCarthy PL; Libby EN; Voorhees PM -
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol Volume: 9 Page(s): e403 - e414
06/01/2022 Authors: Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksa M; Legie W; Liberati AM; Goldschmidt H; Belch A -
BCMA CAR-T AFTER ALLOGENEIC HCT INDUCES REMISSION IN REFRACTORY PLASMABLASTIC LYMPHOMA
Volume: 69
06/01/2022 Authors: Raghunandan S; Pauly M; Blum W; Qayed M; Dhodapkar M; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S -
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Blood Cancer J Volume: 12 Page(s): 63
04/13/2022 Authors: Nooka AK; Kaufman JL; Rodriguez C; Jakubowiak A; Efebera Y; Reeves B; Wildes T; Holstein SA; Anderson LD; Badros A -
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Pharmacotherapy Volume: 42 Page(s): 233 - 240
03/01/2022 Authors: Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK -
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT -
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
Lancet Haematol Volume: 9 Page(s): e143 - e161
02/01/2022 Authors: Raje NS; Anaissie E; Kumar SK; Lonial S; Martin T; Gertz MA; Krishnan A; Hari P; Ludwig H; O'Donnell E -
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.
Cancer Med Volume: 11 Page(s): 358 - 370
01/01/2022 Authors: Pan D; Kaufman JL; Htut M; Agrawal M; Mazumder A; Cornell RF; Zonder JA; Fay JW; Modiano MR; Moshier EL -
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States.
Patient Prefer Adherence Volume: 16 Page(s): 573 - 585
01/01/2022 Authors: Auclair D; Mansfield C; Fiala MA; Chari A; Cole CE; Kaufman JL; Orloff GJ; Siegel DS; Zonder JA; Mange B -
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
J Clin Oncol Volume: 39 Page(s): 3602 - 3612
11/10/2021 Authors: Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho S-J; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S -
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
Blood Cancer Discov Volume: 2 Page(s): 600 - 615
11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC -
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Blood Adv Volume: 5 Page(s): 3748 - 3759
10/12/2021 Authors: Costa LJ; Davies FE; Monohan GP; Kovacsovics T; Burwick N; Jakubowiak A; Kaufman JL; Hong W-J; Dail M; Salem AH -
Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants
Volume: 21 Page(s): S129 - S129
10/01/2021 Authors: Andrews J; Gleason C; Dhodapkar MV; Lonial S; Kaufman J; Nooka A -
Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
Volume: 21 Page(s): S439 - S440
09/01/2021 Authors: Hultcrantz M; Anderson LD; Anwer F; Gasparetto C; Kocoglu MH; Lichtman EI; Mo C; Niesvizky R; Lewis E; Li H -
Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Volume: 21 Page(s): S396 - S397
09/01/2021 Authors: Santapuram P; Rupji M; Graiser M; Waller E; Blum K; Allen P; Koff J; Heffner L; Lechowicz M; Lonial S -
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Leuk Lymphoma Volume: 62 Page(s): 1721 - 1729
07/01/2021 Authors: Khan S; LeBlanc R; Gyger M; White D; Kaufman J; Jazubowiak A; Gul E; Paul H; Le LW; Lau A -
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Blood Volume: 137 Page(s): 3604 - 3615
07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT -
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Haematologica Volume: 106 Page(s): 1725 - 1732
06/01/2021 Authors: San-Miguel J; Usmani SZ; Mateos M-V; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K -
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Am J Hematol Volume: 96 Page(s): 418 - 427
04/01/2021 Authors: Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F -
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Am J Hematol Volume: 96 Page(s): E68 - E71
03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH -
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma.
Blood Lymphat Cancer Volume: 11 Page(s): 11 - 24
01/01/2021 Authors: Gupta VA; Ackley J; Kaufman JL; Boise LH -
Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Blood Cancer J Volume: 10 Page(s): 125
12/14/2020 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S -
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
Leukemia Volume: 34 Page(s): 3298 - 3309
12/01/2020 Authors: Mikhael J; Richter J; Vij R; Cole C; Zonder J; Kaufman JL; Bensinger W; Dimopoulos M; Lendvai N; Hari P -
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 797 - 803
12/01/2020 Authors: Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT -
Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study Update
Volume: 55 Page(s): 127 - 128
12/01/2020 Authors: Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD -
Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center
Volume: 136
11/05/2020 Authors: Maples KT; Brechtelsbauer E; Pendexter J; Kaufman JL; Joseph N; Heffner L; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka A -
Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
Volume: 136
11/05/2020 Authors: Santapuram PR; Rupji M; Graiser M; Waller EK; Blum KA; Allen PB; Koff JL; Heffner L; Lechowicz MJ; Lonial S -
Role of clonoSEQ (R), a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
Volume: 136
11/05/2020 Authors: Nooka A; Bradley K; Joseph N; Hofmeister CC; Dhodapkar MV; Boise LH; Lonial S; Li S; Kaufman JL -
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Blood Cancer J Volume: 10 Page(s): 111
11/03/2020 Authors: Kaufman JL; Dimopoulos MA; White D; Benboubker L; Cook G; Leiba M; Morton J; Joy Ho P; Kim K; Takezako N -
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood Volume: 136 Page(s): 936 - 945
08/20/2020 Authors: Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD -
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood Volume: 136 Page(s): 71 - 80
07/02/2020 Authors: Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL -
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Leukemia Volume: 34 Page(s): 1875 - 1884
07/01/2020 Authors: Bahlis NJ; Dimopoulos MA; White DJ; Benboubker L; Cook G; Leiba M; Ho PJ; Kim K; Takezako N; Moreau P -
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
J Clin Oncol Volume: 38 Page(s): 1928 - 1937
06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK -
Real-world outcomes of venetoclax refractory multiple myeloma patients.
Volume: 38
05/20/2020 Authors: Maples KT; Kaufman JL; Gupta VA; Joseph N; Heffner LT; Hofmeister CC; Dhodapkar M; Matulis SM; Boise L; Lonial S -
Efficacy of daratumumab plus SOC versus SOC in myeloma induction regimens, by risk-stratification: Meta-analysis of phase III randomized control trials.
Volume: 38
05/20/2020 Authors: Joseph N; Hofmeister CC; Dhodapkar M; Boise L; Lonial S; Behera M; Kaufman JL; Nooka AK -
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.
Blood Cancer J Volume: 10 Page(s): 40
04/14/2020 Authors: Mina R; Joseph NS; Gay F; Kastritis E; Petrucci MT; Kaufman JL; Montefusco V; Gavriatopoulou M; Patriarca F; Omed P -
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
J Clin Oncol Volume: 38 Page(s): 1126 - 1137
04/10/2020 Authors: Lonial S; Jacobus S; Fonseca R; Weiss M; Kumar S; Orlowski RZ; Kaufman JL; Yacoub AM; Buadi FK; O'Brien T -
Four-year follow-up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma
Volume: 189 Page(s): 20 - 20
04/01/2020 Authors: Cook G; Kaufman JL; Usmani SZ; San-Miguel J; Bahlis NJ; White D; Benboubker L; Leiba M; Ho PJ; Kim K -
Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma
Volume: 26 Page(s): S269 - S270
03/01/2020 Authors: Nishihori T; Kaufman JL; Hoffrnan JE; Blouch K; Pandit S; Butler E; Jain A; Wu Y; DeYoung MP; Hasan AN -
Roundtable: How I treat a newly diagnosed patient with high-risk myeloma.
Hematology Am Soc Hematol Educ Program Volume: 2019 Page(s): 120 - 124
12/06/2019 Authors: Kaufman JL -
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Blood Cancer J Volume: 9 Page(s): 94
11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J -
The Role of Proteasome Activator PA28 alpha in Multiple Myeloma
Volume: 134
11/13/2019 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman JL; Nooka AK; Gupta VA; Dhodapkar MV; Boise LH; Lonial S -
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Volume: 134
11/13/2019 Authors: Bernal-Mizrachi L; Nooka AK; Heffner L; Cole CE; Ye JC; Vij R; Hofmeister CC; Rushton J; Chen Z; Chang Z -
Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma
Volume: 134
11/13/2019 Authors: Nishihori T; Kaufman JL; Hoffman JE; Blouch K; Pandit S; Butler E; Jain A; Wu Y; DeYoung MP; Hasan AN -
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis
Volume: 94 Page(s): S31 - S31
11/01/2019 Authors: Chari A; Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Silbermann R; Costa LJ; Anderson LD -
Architecture of human Rag GTPase heterodimers and their complex with mTORC1.
Science Volume: 366 Page(s): 203 - 210
10/11/2019 Authors: Anandapadamanaban M; Masson GR; Perisic O; Berndt A; Kaufman J; Johnson CM; Santhanam B; Rogala KB; Sabatini DM; Williams RL -
Daratumumab plus Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
Volume: 19 Page(s): E353 - E354
10/01/2019 Authors: Voorhees P; Kaufman JL; Laubach J; Sborov D; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa L; Anderson L -
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Volume: 19 Page(s): E243 - E244
10/01/2019 Authors: Bernal L; Nooka A; Cole C; Heffner LT; Ye JC; Vij R; Chen Z; Zhang C; Rushton J; Munevver C -
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Volume: 125 Page(s): 2991 - 3000
09/01/2019 Authors: Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S -
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Blood Volume: 134 Page(s): 668 - 677
08/22/2019 Authors: Usmani SZ; Nahi H; Mateos M-V; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L -
A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstrm Macroglobulinemia.
Clin Cancer Res Volume: 25 Page(s): 4907 - 4916
08/15/2019 Authors: Ghobrial IM; Vij R; Siegel D; Badros A; Kaufman J; Raje N; Jakubowiak A; Savona MR; Obreja M; Berdeja JG -
Daratumumab in multiple myeloma.
Cancer Volume: 125 Page(s): 2364 - 2382
07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S -
Registering a CD38 antibody upfront for multiple myeloma.
Lancet Volume: 394 Page(s): 3 - 4
07/06/2019 Authors: Hofmeister CC; Nooka A; Kaufman JL; Lonial S -
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Leukemia Volume: 33 Page(s): 1736 - 1746
07/01/2019 Authors: Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R -
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies.
Cancer Volume: 125 Page(s): 2322 - 2324
07/01/2019 Authors: Harvey RD; Zhang C; Lonial S; Kaufman JL; Chen Z -
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 332 - 344
06/01/2019 Authors: Ghobrial I; Cruz CH; Garfall A; Shah N; Munshi N; Kaufman J; Boise LH; Morgan G; Adalsteinsson VA; Manier S -
Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.
Volume: 37
05/20/2019 Authors: Kaufman JL; Dimopoulos MA; Leiba M; Morton J; Ho PJ; Kim K; Moreau P; Sutherland HJ; Iida S; Kim JS -
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Leukemia Volume: 33 Page(s): 1291 - 1296
05/01/2019 Authors: Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL -
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
JCI Insight Volume: 5
04/23/2019 Authors: Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL -
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Nat Commun Volume: 10 Page(s): 1911
04/23/2019 Authors: Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D -
Venetoclax Monotherapy and Combined with Dexamethasone as Targeted Therapy for Relapsed/Refractory t(11;14) Multiple Myeloma
Volume: 185 Page(s): 182 - 183
03/01/2019 Authors: Kaufman J; Gasparetto C; Mikhael J; Moreau P; Touzeau C; Vij R; Facon T; Pegourie B; Benboubker L; Boise L -
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Cancer Volume: 125 Page(s): 416 - 423
02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK -
Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Cancer Volume: 125 Page(s): 185 - 193
01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR -
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Blood Cancer J Volume: 9 Page(s): 3
01/04/2019 Authors: Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT -
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
JAMA Oncol Volume: 4 Page(s): e183267
12/01/2018 Authors: Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS -
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Haematologica Volume: 103 Page(s): 2088 - 2096
12/01/2018 Authors: Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K -
Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial
Volume: 132
11/29/2018 Authors: Vij R; Nathwani N; Martin TG; Fiala MA; Deol A; Buadi FK; Kaufman JL; Hofmeister CC; Gregory T; Berdeja JG -
Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Volume: 132
11/29/2018 Authors: Clemens PL; Xu S; Luo M; Chari A; Usmani SZ; Mateos M-V; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A -
A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Volume: 132
11/29/2018 Authors: Hari P; Schroeder MA; Berenson JR; Jakubowiak A; Kaufman JL; Voorhees PM; Fujii H; Yang Z; Galimi F; Shain KH -
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Volume: 132
11/29/2018 Authors: Chari A; Mateos M-V; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Nahi H; Tang J -
Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy
Volume: 132
11/29/2018 Authors: Barwick BG; Neri P; Bahlis N; Nooka AK; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM -
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
Cancer Volume: 124 Page(s): 4358 - 4365
11/15/2018 Authors: Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD -
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.
J Oncol Pract Volume: 14 Page(s): 561 - 564
09/01/2018 Authors: Chang A; Nasti TH; Khan MK; Parashar S; Kaufman JL; Boise LH; Lonial S; Ahmed R; Nooka AK -
Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population
Volume: 18 Page(s): S250 - S251
09/01/2018 Authors: Schmidt T; Mina R; Joseph N; Gay F; Nooka A; Kastritis E; Spada S; Kaufman J; Montefusco V; Gilestro M -
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Biol Blood Marrow Transplant Volume: 24 Page(s): 1187 - 1195
06/01/2018 Authors: Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD -
Novel Approaches for the Management of AL Amyloidosis.
Curr Hematol Malig Rep Volume: 13 Page(s): 212 - 219
06/01/2018 Authors: Joseph NS; Kaufman JL -
Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
Volume: 36
05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK -
Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
Volume: 36
05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK -
Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma
Volume: 181 Page(s): 100 - 101
04/01/2018 Authors: Kumar S; Kaufman JL; Mikhael J; Gasparetto C; Vij R; Pegourie B; Benboubker L; Facon T; Moreau P; Amiot M -
14-3-3 binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
Leukemia Volume: 32 Page(s): 744 - 751
03/01/2018 Authors: Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A -
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
Clin Lymphoma Myeloma Leuk Volume: 18 Page(s): 163 - 173.e6
03/01/2018 Authors: Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L -
Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT)
Volume: 24 Page(s): S135 - S136
03/01/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff J; Gupta V; Lechowicz M; Al-Kadhimi Z; Nooka A; Kaufman J; Lonial S -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
Volume: 130
12/07/2017 Authors: Joseph N; Almaula D; Gleason C; Heffner L; Boise LH; Kaufman JL; Lonial S; Nooka A -
A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma
Volume: 130
12/07/2017 Authors: Gupta VA; Barwick B; Newman S; Keats JJ; Auclair D; Matulis S; Rossi MR; Nooka AK; Kaufman JL; Lonial S -
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer Volume: 123 Page(s): 4617 - 4630
12/01/2017 Authors: Shah JJ; Kaufman JL; Zonder JA; Cohen AD; Bensinger WI; Hilder BW; Rush SA; Walker DH; Tunquist BJ; Litwiler KS -
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Blood Volume: 130 Page(s): 2401 - 2409
11/30/2017 Authors: Kumar S; Kaufman JL; Gasparetto C; Mikhael J; Vij R; Pegourie B; Benboubker L; Facon T; Amiot M; Moreau P -
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Blood Volume: 130 Page(s): 974 - 981
08/24/2017 Authors: Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R -
High-risk Multiple Myeloma: Definition and Management.
Clin Lymphoma Myeloma Leuk Volume: 17S Page(s): S80 - S87
07/01/2017 Authors: Joseph NS; Gentili S; Kaufman JL; Lonial S; Nooka AK -
VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Volume: 102 Page(s): 268 - 269
06/26/2017 Authors: Kumar S; Kaufman JL; Mikhael J; Gasparetto C; Vij R; Pegourie B; Benboubker L; Facon T; Moreau P; Amiot M -
DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT
Volume: 102 Page(s): 142 - +
06/26/2017 Authors: Kumar S; Berdeja J; Niesvizky R; Lonial S; Laubach J; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R -
EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
Volume: 102 Page(s): 525 - 526
06/26/2017 Authors: Dimopoulos MA; Weisel K; Kaufman J; Sonneveld P; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L -
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Blood Volume: 129 Page(s): 1969 - 1979
04/06/2017 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH -
New Treatment Strategies Making an Impact in Multiple Myeloma.
J Adv Pract Oncol Volume: 8 Page(s): 285 - 290
04/01/2017 Authors: Gleason C; Kaufman J -
Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with >= 2 Prior Lines of Therapy
Volume: 17 Page(s): E14 - E15
02/01/2017 Authors: Chari A; Suvannasankha A; Fay J; Arnulf B; Kaufman JL; Ifthikharuddin J; Weiss BM; Krishnan A; Lentzsch S; Comenzo R -
Survival Outcomes of Younger (<= 50 years) Myeloma Patients
Volume: 17 Page(s): E119 - E119
02/01/2017 Authors: Almaula D; Joseph N; Kaufman JL; Heffner LT; Liu Y; Zhang C; Boise L; Lonial S; Nooka A -
Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients
Volume: 17 Page(s): E68 - E69
02/01/2017 Authors: Joseph N; Kaufman J; Boise L; Almaula D; Langston A; Waller E; Khoury H; Heffner LT; Lonial S; Nooka A -
Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma
Volume: 17 Page(s): E27 - E27
02/01/2017 Authors: Kumar S; Kaufman JL; Mikhael J; Gasparetto C; Vij R; Pegourie B; Benboubker L; Facon T; Moreau P; Amiot M -
Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX
Volume: 17 Page(s): E116 - E116
02/01/2017 Authors: Dimopoulos M; Belch AR; White DJ; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N -
Efficacy and Safety of Daratumumab-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma - A Systematic Literature Review and Network Meta-analysis
Volume: 17 Page(s): E63 - E63
02/01/2017 Authors: Dimopoulos M; Weisel K; Kaufman JL; Sonneveld P; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Lam A -
Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX
Volume: 17 Page(s): E17 - E18
02/01/2017 Authors: San-Miguel J; Dimopoulos MA; Usmani S; Belch AR; Bahlis NJ; White DJ; Benboubker L; Cook G; Leiba M; Morton J -
The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.
Br J Dermatol Volume: 176 Page(s): 423 - 430
02/01/2017 Authors: Tiao J; Feng R; Bird S; Choi JK; Dunham J; George M; Gonzalez-Rivera TC; Kaufman JL; Khan N; Luo JJ -
Insights Into the Appropriate Use of New Antimyeloma Therapies.
Oncology (Williston Park) Volume: 31 Page(s): 64 - 66
01/15/2017 Authors: Kaufman JL; Lonial S -
Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.
Bone Marrow Transplant Volume: 52 Page(s): 132 - 134
01/01/2017 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Al-Kadhimi Z; Cohen JB; Flowers CR -
Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant
Volume: 128
12/02/2016 Authors: Kumar P; Joseph N; Almaula D; Boise LH; Kaufman JL; Gleason C; Lonial S; Nooka AK -
Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux
Volume: 128
12/02/2016 Authors: Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince M; Cochrane T; Khokhar NZ -
Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
Volume: 128
12/02/2016 Authors: Nooka AK; Wang M; Yee AJ; Thomas SK; O'Donnell EK; Shah JJ; Kaufman JL; Peterkin D; Lonial S; Richardson PG -
B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma
Volume: 128
12/02/2016 Authors: Gupta VA; Newman S; Bahlis NJ; Keats JJ; Matulis S; Rossi MR; Auclair D; Nooka AK; Kaufman JL; Lonial S -
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Cancer Volume: 122 Page(s): 3327 - 3335
11/15/2016 Authors: Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW -
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Expert Opin Biol Ther Volume: 16 Page(s): 1291 - 1301
10/01/2016 Authors: Lonial S; Kaufman J; Reece D; Mateos M-V; Laubach J; Richardson P -
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Volume: 17 Page(s): 769 - 777
07/02/2016 Authors: Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Blood Volume: 127 Page(s): 2693 - 2700
06/02/2016 Authors: Richardson PG; Zimmerman TM; Hofmeister CC; Talpaz M; Chanan-Khan AA; Kaufman JL; Laubach JP; Chauhan D; Jakubowiak AJ; Reich S -
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 16 Page(s): 329 - 334.e1
06/01/2016 Authors: Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T -
PHASE 1 STUDY OF VENETOCLAX MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Volume: 101 Page(s): 328 - 328
06/01/2016 Authors: Kumar S; Vij R; Kaufman JL; Mikhael J; Facon T; Pegourie B; Benboubker L; Gasparetto C; Amiot M; Moreau P -
UPDATED DATA FROM A PHASE II DOSE FINDING TRIAL OF SINGLE AGENT ISATUXIMAB (SAR650984, ANTI-CD38 MAB) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Volume: 101 Page(s): 82 - 83
06/01/2016 Authors: Vij R; Martin T; Richter J; Cole C; Atanackovic D; Zonder J; Kaufman J; Mikhael J; Bensinger W; Dimopoulos M -
Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: Meta-analysis of phase 3 randomized controlled trials.
Volume: 34
05/20/2016 Authors: Nooka AK; Kaufman JL; Lonial S -
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Oncotarget Volume: 7 Page(s): 27753 - 27763
05/10/2016 Authors: Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J -
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Leukemia Volume: 30 Page(s): 1086 - 1093
05/01/2016 Authors: Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH -
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
J Clin Oncol Volume: 34 Page(s): 1544 - 1557
05/01/2016 Authors: Dimopoulos MA; Sonneveld P; Leung N; Merlini G; Ludwig H; Kastritis E; Goldschmidt H; Joshua D; Orlowski RZ; Powles R -
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Volume: 16 Page(s): 129 - 138
03/01/2016 Authors: Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Gupta M; Tendolkar A; Lynch M; Bleickardt E -
Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Collins H; Gupta VA; Boise LH; Lonial S -
Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Kendi ATK; Li Y; Obidike CO; Gleason C; Boise LH; Lonial S -
Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
Volume: 126
12/03/2015 Authors: Nooka AK; Wang M; Yee AJ; Thomas SK; O'Donnell EK; Shah JJ; Kaufman JL; Lonial S; Richardson PG; Raje NS -
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results
Volume: 126
12/03/2015 Authors: Kumar SK; Vij R; Kaufman JL; Mikhael JR; Facon T; Pegourie B; Benboubker L; Moreau P; Amiot M; Alzate S -
A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma
Volume: 126
12/03/2015 Authors: Martin T; Richter J; Vij R; Cole C; Atanackovic D; Zonder J; Kaufman JL; Bensinger W; Dimopoulos MA; San Miguel J -
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Blood Volume: 126 Page(s): 2284 - 2290
11/12/2015 Authors: Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL -
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Volume: 171 Page(s): 539 - 546
11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ -
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Transfusion Volume: 55 Page(s): 2351 - 2357
10/01/2015 Authors: Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C -
How I treat high-risk myeloma.
Blood Volume: 126 Page(s): 1536 - 1543
09/24/2015 Authors: Lonial S; Boise LH; Kaufman J -
VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE I SAFETY AND EFFICACY
Volume: 100 Page(s): 256 - 257
06/01/2015 Authors: Kumar S; Vij R; Kaufman JL; Mikhael J; Facon T; Moreau P; Amiot M; Alzate S; Morris L; Ross J -
UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA
Volume: 100 Page(s): 461 - 461
06/01/2015 Authors: Siegel D; Kaufman JL; Raje N; Mikhael J; Kapoor P; Treon S; Castillo J; Neuman L; Obreja M; Ghobrial I -
UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM)
Volume: 100 Page(s): 251 - 251
06/01/2015 Authors: Vij R; Savona M; Siegel D; Kaufman JL; Badros A; Ghobrial I; Paner A; Jagannath S; Jakubowiak A; Mikhael J -
Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.
Volume: 33
05/20/2015 Authors: Obidike CO; Nooka AK; Kaufman JL; Heffner LT; Langston AA; Lonial S -
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
Volume: 33
05/20/2015 Authors: Kumar S; Vij R; Kaufman JL; Mikhael J; Facon T; Moreau P; Amiot M; Alzate S; Morris LJ; Ross JA -
Pharmacokinetics and safety of elotuzumab in combination with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal function: updated results of a phase 1b study
Volume: 169 Page(s): 69 - 70
04/01/2015 Authors: Paliwal P; Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Lynch M; Bleickardt E; Vij R -
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
CANCER Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
Leuk Lymphoma Volume: 56 Page(s): 383 - 389
02/01/2015 Authors: Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L -
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results
Volume: 124
12/06/2014 Authors: Kumar S; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart K; Hari PN; Roy V; Vescio R -
Detection of NFKB2 3'end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma
Volume: 124
12/06/2014 Authors: Ramachandiran S; Koff JL; Garderet L; Saxe D; Ikhlef S; Kelkar N; Kaplan L; El-Cheikh J; Switchenko JM; Sunay S -
Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma
Volume: 124
12/06/2014 Authors: Matulis S; Nooka AK; Von Hollen H; Kaufman JL; Lonial S; Boise LH -
Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant
Volume: 124
12/06/2014 Authors: Pooja C; Nooka AK; Chatwal MS; Kim S; Chen Z; Kowalski J; Kaufman JL; Lonial S; Bernal-Mizrachi L -
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Volume: 124
12/06/2014 Authors: Kaufman JL; Zimmerman T; Rosenbaum CA; Nooka AK; Heffner LT; Harvey RD; Gleason C; Lewis C; Sharp C; Barron KW -
Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study
Volume: 124
12/06/2014 Authors: Vij R; Savona M; Siegel DS; Kaufman JL; Badros A; Ghobrial IM; Paner A; Jagannath S; Jakubowiak A; Mikhael JR -
Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstrom Macroglobulinemia (WM)
Volume: 124
12/06/2014 Authors: Siegel DS; Kaufman JL; Raje NS; Mikhael JR; Kapoor P; Treon SP; Castillo JJ; Neuman LL; Lee JR; Ghobrial I -
Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)
Volume: 124
12/06/2014 Authors: Siegel DS; Berdeja JG; Infante JR; Kaufman JL; Wang ML; Martin TG; Niesvizky R; Reu FJ; Jagannath S; Rajangam K -
A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Volume: 124
12/06/2014 Authors: Cohen AD; Scott EC; Liedtke M; Kaufman JL; Landau H; Vesole DH; Gomes CL; Gasparetto C; Lentzsch S; Rosenzweig M -
Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies
BLOOD Volume: 124
12/06/2014 Authors: Bernal-Mizrachi L; Nooka AK; Pooja C; Chatwal MS; Kim S; Chen Z; Kowalski J; Kaufman JL; Lonial S -
Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
BLOOD Volume: 124
12/06/2014 Authors: Gleason C; Kaufman JL; Nooka AK; Valla K; Heffner LT; Bisht AS; Manubolu S; Watson M; Boise LH; Lonial S -
Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
BLOOD Volume: 124
12/06/2014 Authors: Wang ML; Nooka AK; Yee AJ; Thomas SK; O'Donnell E; Shah J; Weber DM; Kaufman JL; Lonial S; Avigan D -
Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e213 - e215
12/01/2014 Authors: Shams SR; Goldstein DA; Kaufman JL; MacKelfresh J; Flowers CR; Langston AA -
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Lancet Oncol Volume: 15 Page(s): 1503 - 1512
12/01/2014 Authors: Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R -
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol Volume: 15 Page(s): 1195 - 1206
10/01/2014 Authors: San-Miguel JF; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Gnther A; Nakorn TN; Siritanaratkul N -
The Tao of myeloma.
Blood Volume: 124 Page(s): 1873 - 1879
09/18/2014 Authors: Boise LH; Kaufman JL; Bahlis NJ; Lonial S; Lee KP -
Transcriptional and Post-translational Regulation of the BcI-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S148 - S148
09/01/2014 Authors: Gupta VA; Matulis SM; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant Volume: 20 Page(s): 852 - 857
06/01/2014 Authors: Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S -
A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Volume: 99 Page(s): 113 - 113
06/01/2014 Authors: Chari A; Htut M; Zonder J; Fay J; Jakubowiak A; Harrison B; Lau K; Burt S; Hilder B; Ptaszynski AM -
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Blood Volume: 123 Page(s): 3269 - 3276
05/22/2014 Authors: Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun S-Y; Boise LH; Lonial S -
Survival trends of myeloma patients in the new millennium.
Volume: 32
05/20/2014 Authors: Gleason C; Nooka AK; Langston AA; Shah NN; Kaufman JL; Lonial S -
Causes of mortality in patients with plasma cell disorders.
Volume: 32
05/20/2014 Authors: Nooks AK; Kaufman JL; Langston AA; Lonial S -
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e59 - e63
04/01/2014 Authors: Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL -
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Blood Volume: 123 Page(s): 1461 - 1469
03/06/2014 Authors: Richardson PG; Xie W; Jagannath S; Jakubowiak A; Lonial S; Raje NS; Alsina M; Ghobrial IM; Schlossman RL; Munshi NC -
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Leukemia Volume: 28 Page(s): 690 - 693
03/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S -
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
Bone Marrow Transplant Volume: 49 Page(s): 185 - 189
02/01/2014 Authors: Langston AA; Prichard JM; Muppidi S; Nooka A; Lechowicz MJ; Lonial S; Sinha R; Graiser M; Kaufman JL; Khoury HJ -
Simplified Technique for Administration of High Dose Melphalan
Volume: 20 Page(s): S291 - S292
02/01/2014 Authors: Hutcherson D; Valla K; Shah KS; Surati M; French K; Nooka A; Kaufman J; Lonial S; Cohen JB; Langston A -
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Cancer Volume: 119 Page(s): 4119 - 4128
12/01/2013 Authors: Nooka AK; Kaufman JL; Behera M; Langston A; Waller EK; Flowers CR; Gleason C; Boise LH; Lonial S -
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT -
Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.
Expert Opin Biol Ther Volume: 13 Page(s): 1731 - 1740
12/01/2013 Authors: Lonial S; Kaufman J; Laubach J; Richardson P -
Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Rossi MR; Newman S; Nooka AK; Kaufman JL; Bahlis NJ; Neri P; Matulis SM; Bernal-Mizrachi L; Gupta VA; Varma A -
Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Harvey D; Kaufman JL; Langston A; Nickleach D; Gleason C; Heffner LT; Boise LH; Lonial S -
Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Kaufman JL; Casbourne D; Hutcherson D; Maynard R; Waller EK; Lonial S; Langston A -
Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low alpha-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study
Volume: 122
11/15/2013 Authors: Lonial S; Shah JJ; Zonder J; Bensinger WI; Cohen AD; Kaufman JL; Nooka AK; Weber DM; Hilder B; Rush SA -
Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample
Volume: 122
11/15/2013 Authors: Nooka AK; Kaufman JL; Shah NN; Langston A; Collins H; Boise LH; Lonial S -
Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT)
Volume: 122
11/15/2013 Authors: Gowda S; Langston A; Kaufman JL; Shah NN; Lechowicz MJ; Boise LH; Lonial S; Nooka AK -
Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC)
BLOOD Volume: 122
11/15/2013 Authors: Nooks AK; Kaufman JL; Shah NN; Hassan B; Boise LH; Williams I; Lonial S -
A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)
Volume: 122
11/15/2013 Authors: Chari A; Htut M; Zonder J; Fay JW; Jakubowiak AJ; Harrison B; Lau K; Hilder B; Ptaszynski A; Rush SA -
Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma
Volume: 122
11/15/2013 Authors: Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger W; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Orlowski RZ -
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
Br J Haematol Volume: 163 Page(s): 478 - 486
11/01/2013 Authors: Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Wegener WA; Goldenberg DM -
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Biol Blood Marrow Transplant Volume: 19 Page(s): 1393 - 1395
09/01/2013 Authors: Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S -
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Ann Pharmacother Volume: 47 Page(s): 1136 - 1142
09/01/2013 Authors: Barbee MS; Harvey RD; Lonial S; Kaufman JL; Wilson NM; McKibbin T; Hutcherson DA; Surati M; Valla K; Shah KS -
Non-secretory myeloma: a clinician's guide.
Oncology (Williston Park) Volume: 27 Page(s): 924 - 930
09/01/2013 Authors: Lonial S; Kaufman JL -
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 370 - 376
08/01/2013 Authors: Kaufman JL; Fabre C; Lonial S; Richardson PG -
ELIMINATING THE NEED FOR 24-HOUR URINE STUDIES IN PHASE I MYELOMA PATIENTS
Volume: 98 Page(s): 598 - 598
06/12/2013 Authors: Shah N; Kaufman J; Langston A; Waller E; Boise L; Harvey R; Lonial S; Nooka A -
ALPHA 1-ACID GLYCOPROTEIN (AAG) IS A POTENTIAL PATIENT SELECTION BIOMARKER FOR IMPROVED CLINICAL ACTIVITY OF ARRY-520 IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM)
Volume: 98 Page(s): 328 - 329
06/12/2013 Authors: Tunquist B; Brown K; Hingorani G; Aitchison R; Regensburger J; Lonial S; Kaufman J; Zonder J; Cohen A; Bensinger W -
CLINICAL PROFILE OF ONCE-DAILY, MODIFIED-RELEASE OPROZOMIB TABLETS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: RESULTS OF A PHASE 1B/2 TRIAL
Volume: 98 Page(s): 100 - 101
06/12/2013 Authors: Kaufman J; Siegel D; Vij R; Ghobrial I; Badros A; Neuman L; Anderl J; Savona M -
Prolonged carfilzomib therapy: results of a phase 2 study of patients with multiple myeloma previously enrolled in carfilzomib phase 1 and 2 clinical trials
LEUKEMIA & LYMPHOMA Volume: 54 Page(s): 18 - 19
06/01/2013 Authors: Siegel DS; Wang M; Martin T; Infante JR; Kaufman J; Rajangam K; Huang M; Bilotti E; Vij R -
Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.
Volume: 31
05/20/2013 Authors: Duc QT; Langston AA; Waller EK; Simon M; Gleason C; Casbourne D; Fisher M; Kaufman JL; Flowers C; Lonial S -
Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis
Volume: 31
05/20/2013 Authors: Ravipati HP; Kaufman JL; Langston AA; Boise L; Flowers C; Lonial S; Nooka AK -
Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
Volume: 31
05/20/2013 Authors: Nooka AK; Langston AA; Waller EK; Heffner LT; Gleason C; Muppidi S; Watson M; Casbourne D; Boise L; Kaufman JL -
Risk-adapted maintenance therapy (MaintRx) after ASCT in first-line therapy for multiple myeloma (MM)
Volume: 31
05/20/2013 Authors: Kaufman JL; Willey J; Williams ME; Tiscione B; Buettner A; Neely D; Green MR -
Single centre pharmacoeconomic analysis of palifermin in autologous stem cell transplantation
Volume: 48 Page(s): S453 - S453
04/01/2013 Authors: Johnson HR; Nooka A; Kaufman J; Flowers C; Langston A; Graiser M; Plummer T; Lonial S; Waller E -
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 159 - 161
04/01/2013 Authors: Wilson N; Surati M; Walker BF; Kaufman JL; Harvey RD -
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
Biol Blood Marrow Transplant Volume: 19 Page(s): 460 - 467
03/01/2013 Authors: Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK -
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
J Clin Oncol Volume: 31 Page(s): 573 - 583
02/10/2013 Authors: Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G -
Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
Volume: 19 Page(s): S191 - S191
02/01/2013 Authors: Waller EK; Johnson HR; Jagirdar N; Gaylor C; Lipscomb C; Flowers C; Kaufman J; Khoury HJ; Langston A; Lechowicz M -
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
Transfusion Volume: 53 Page(s): 76 - 84
01/01/2013 Authors: Kaufman JL; Flowers CR; Rados KD; Calandra GB; Vose JM; Hewes LB; Lonial S; Langston AA; Khoury HJ; Lechowicz MJ -
The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study
Volume: 120
11/16/2012 Authors: Shah JJ; Zonder JA; Cohen A; Bensinger W; Kaufman JL; Orlowski RZ; Harvey RD; Abidi MH; Thomas SK; Walker D -
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH -
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH -
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK -
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK -
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
Br J Haematol Volume: 158 Page(s): 608 - 614
09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L -
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Br J Haematol Volume: 158 Page(s): 472 - 480
08/01/2012 Authors: Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T -
CARFILZOMIB DOSE AND SCHEDULE NEED NOT BE ADJUSTED FOR BASELINE RENAL DYSFUNCTION, INCLUDING PATIENTS ON HEMODIALYSIS
Volume: 97 Page(s): 346 - 346
07/16/2012 Authors: Harvey D; Lonial S; Patel P; McCulloch L; Niesvizky R; Kaufman J -
PLASMA CELL LEUKEMIA: SUSTAINED RESPONSES ARE POSSIBLE WITH INNOVATIVE TREATMENT STRATEGIES
Volume: 97 Page(s): 601 - 601
07/16/2012 Authors: Nooka A; Kaufman J; Muppidi S; Harvey R; Gleason C; Heffner L; Langston A; Casbourne D; Boise L; Lonial S -
VANTAGE 095: FINAL RESULTS FROM A GLOBAL, SINGLE-ARM, PHASE 2B TRIAL OF VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN SALVAGE MULTIPLE MYELOMA PATIENTS
Volume: 97 Page(s): 119 - 119
07/16/2012 Authors: Siegel D; Dimopoulos M; Yoon S; Laubach J; Kaufman J; Goldschmidt H; Reece D; Leleu X; Durrant S; Offner F -
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Cancer Volume: 118 Page(s): 3538 - 3548
07/15/2012 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT -
The era of combination therapy in myeloma.
J Clin Oncol Volume: 30 Page(s): 2434 - 2436
07/10/2012 Authors: Lonial S; Kaufman JL -
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood Volume: 119 Page(s): 5661 - 5670
06/14/2012 Authors: Vij R; Wang M; Kaufman JL; Lonial S; Jakubowiak AJ; Stewart AK; Kukreti V; Jagannath S; McDonagh KT; Alsina M -
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
J Clin Oncol Volume: 30 Page(s): 1953 - 1959
06/01/2012 Authors: Lonial S; Vij R; Harousseau J-L; Facon T; Moreau P; Mazumder A; Kaufman JL; Leleu X; Tsao LC; Westland C -
Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
Volume: 30
05/20/2012 Authors: Harvey RD; Lonial S; Patel P; McCulloch L; Niesvizky R; Kaufman JL -
An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Barbee MS; Wilson NM; Harvey RD; McKibbin T; Lonial S; Kaufman JL; Shah KS -
Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
Volume: 30
05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L -
Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
Volume: 30
05/20/2012 Authors: Nooka AK; Badros AZ; Patel P; McCulloch L; Lonial S; Kaufman JL -
Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
Volume: 30
05/20/2012 Authors: Nooka AK; Badros AZ; Patel P; McCulloch L; Lonial S; Kaufman JL -
Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Kaufman JL; Nooka AK; Muppidi S; Heffner LT; Gleason C; Boise L; Lonial S -
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
Leuk Lymphoma Volume: 53 Page(s): 725 - 727
04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M -
Plasma Cell Myeloma Evaluation by Flow Cytometric lmmunophenotyping: Aberrant Antigen Expression and Correlation with Cytogenetic/FISH Abnormalities
Volume: 92 Page(s): 342A - 342A
02/01/2012 Authors: Husman AL; Toscano M; Chandler KL; Lonial S; Kaufman JL; Mann KP -
Plasma Cell Myeloma Evaluation by Flow Cytometric Immunophenotyping: Aberrant Antigen Expression and Correlation with Cytogenetic/FISH Abnormalities
Volume: 25 Page(s): 342A - 342A
02/01/2012 Authors: Husman AL; Toscano M; Chandler KL; Lonial S; Kaufman JL; Mann KP -
Toxicities of mobilized stem cell infusion.
Methods Mol Biol Volume: 904 Page(s): 111 - 115
01/01/2012 Authors: Kaufman JL -
Optimizing stem cell collection through CXCR4 antagonists.
Front Biosci (Schol Ed) Volume: 4 Page(s): 611 - 619
01/01/2012 Authors: Mahaseth H; Kaufman J -
ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
Volume: 118 Page(s): 809 - 810
11/18/2011 Authors: Shah JJ; Zonder J; Cohen A; Orlowski RZ; Alexanian R; Thomas SK; Weber D; Kaufman JL; Harvey RD; Walker D -
A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
BLOOD Volume: 118 Page(s): 1691 - 1691
11/18/2011 Authors: Nooka AK; Muppidi S; Harvey RD; Kaufman JL; Langston A; Lewis C; Boise LH; Flowers CR; Lonial S -
The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Volume: 118 Page(s): 1266 - 1266
11/18/2011 Authors: Lonial S; Cohen A; Zonder J; Benzinger WI; Kaufman JL; Orlowski RZ; Harvey RD; Alexanian R; Thomas SK; Weber D -
Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial
Volume: 118 Page(s): 1287 - 1288
11/18/2011 Authors: Harvey RD; Lonial S; Renfroe H; Sinha R; Flowers CR; Lechowicz MJ; Khoury HJ; Langston A; Waller EK; Kaufman JL -
Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor
Volume: 118 Page(s): 1689 - 1689
11/18/2011 Authors: Matulis SM; Kaufman JL; Lonial S; Boise LH -
Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
Volume: 118 Page(s): 707 - 708
11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT -
Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma
Volume: 118 Page(s): 1248 - 1248
11/18/2011 Authors: Ramachandiran S; Guo X; Garderet L; Ikhlef S; El-cheikh J; Weil MR; Young AN; Bagirov M; Lonial S; Chen Z -
Validation of the Function of 14-3-3 zeta in Multiple Myeloma (MM)
Volume: 118 Page(s): 600 - 601
11/18/2011 Authors: Gu Y; Kaufman JL; Boise LH; Lonial S -
The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 118 Page(s): 1709 - 1710
11/18/2011 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Langston A; Steuer CE; Flowers CR; Boise LH; Lonial S -
Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis
Volume: 118 Page(s): 807 - 808
11/18/2011 Authors: Nooka AK; Behera M; Boise LH; Watson M; Kaufman JL; Lonial S -
MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells
Volume: 118 Page(s): 815 - 816
11/18/2011 Authors: Gu Y; Kaufman JL; Boise LH; Lonial S -
Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis
Volume: 118 Page(s): 855 - 856
11/18/2011 Authors: Prichard JM; Muppidi S; Flowers CR; Kaufman JL; Lechowicz MJ; Lonial S; Nooka AK; Sinha R; Waller EK; Langston A -
Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial
Volume: 118 Page(s): 223 - 224
11/18/2011 Authors: Siegel DS; Dimopoulos MA; Yoon S-S; Laubach JP; Kaufman JL; Goldschmidt H; Reece DE; Leleu X; Durrant S; Offner FC -
Final Results From the Bortezomib-naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
Volume: 118 Page(s): 369 - 370
11/18/2011 Authors: Vii R; Kaufman JL; Jakubowiak AJ; Wang M; Jagannath S; Kukreti V; McDonagh KT; Alsina M; Bahlis NJ; Belch AR -
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Transfusion Volume: 51 Page(s): 2175 - 2182
10/01/2011 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C -
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
Blood Volume: 118 Page(s): 1329 - 1339
08/04/2011 Authors: Morales AA; Kurtoglu M; Matulis SM; Liu J; Siefker D; Gutman DM; Kaufman JL; Lee KP; Lonial S; Boise LH -
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
Transfusion Volume: 51 Page(s): 1779 - 1783
08/01/2011 Authors: Renfroe H; Arnold M; Vaughn L; Harvey RD; Hamilton E; Lonial S; Khoury HJ; Kaufman JL; Lechowicz MJ; Flowers CR -
UPDATED RESULTS FOR BORTEZOMIB (BTZ)-NAIVE PATIENTS (PTS) ENROLLED IN PX-171-004, AN ONGOING OPEN-LABEL, PHASE (PH) 2 STUDY OF CARFILZOMIB (CFZ), IN RELAPSED MULTIPLE MYELOMA (MM)
Volume: 22 Page(s): 200 - 201
06/01/2011 Authors: Kaufman JL; Vesole DH; Stewart A; Jakubowiak AJ; Jagannath S; Kukreti V; Mcdonagh KT; Alsina M; Reu FJ; Orlowski RZ -
Putting the E (evidence) in a new Era for myeloma.
Leuk Lymphoma Volume: 52 Page(s): 349 - 350
03/01/2011 Authors: Kaufman JL; Lonial S -
Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes.
Leukemia Volume: 25 Page(s): 362 - 365
02/01/2011 Authors: Giver CR; Jaye DL; Waller EK; Kaufman JL; Lonial S -
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Blood Volume: 116 Page(s): 5285 - 5288
12/09/2010 Authors: David E; Kaufman JL; Flowers CR; Schafer-Hales K; Torre C; Chen J; Marcus AI; Sun S-Y; Boise LH; Lonial S -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study.
Volume: 116 Page(s): 1251 - 1251
11/19/2010 Authors: Kaufman JL; Shah JJ; Laubach JP; Heffner L; Francis D; Harvey RD; Lewis C; Tighiouart M; Richardson P; Orlowski RZ -
Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth
Volume: 116 Page(s): 1294 - 1294
11/19/2010 Authors: Hitosugi T; Kang S; Vander Heiden M; Chung T-W; Elf S; Lythgoe K; Dong S; Lonial S; Wang X; Chen G -
High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)
Volume: 116 Page(s): 582 - 582
11/19/2010 Authors: Rodriguez TE; Stiff PJ; Smith SE; Kaufman JL; Lee M; Parthasarathy M; Earley ZM; Lonial S; Vesole DH -
Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
Volume: 116 Page(s): 805 - 806
11/19/2010 Authors: Lonial S; Vij R; Harousseau J-L; Facon T; Moreau P; Leleu X; Mazumder A; Kaufman JL; Westland CE; Tsao C -
A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma
Volume: 116 Page(s): 817 - 817
11/19/2010 Authors: Shah JJ; Zonder JA; Cohen A; Weter D; Thomas S; Wang M; Kaufman JL; Burt SM; Walker D; Freeman B -
Cost-Effectiveness Analysis of a "Just-In-Time" Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant.
Volume: 116 Page(s): 923 - 924
11/19/2010 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Repfroe H; Kaufman JL; Lonial S; Flowers CR; Lechowicz MJ; Langston A -
Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil (R)) plus G-CSF In Pediatric Patients with Malignant Disorders.
Volume: 116 Page(s): 923 - 923
11/19/2010 Authors: Shenoy S; Asselin B; Dalal J; Goyal R; Kaufman JL; Loeb D; McCarty J; Robertson K; Strahlendorf C; Walters MC -
Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
Volume: 116 Page(s): 1264 - 1264
11/19/2010 Authors: Jakubowiak AJ; Richardson PG; Zimmerman TM; Alsina M; Kaufman JL; Kandarpa M; Harvey CK; Colson K; Mitchell M; Hideshima T -
Final Analysis: Phase II Study of Oral Panobinostat In Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant
Volume: 116 Page(s): 187 - 187
11/19/2010 Authors: Sureda A; Younes A; Ben-Yehuda D; Ong T-C; Kaufman JL; Le Corre C; Gallagher J; Shen A; Engert A -
Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Volume: 116 Page(s): 814 - 814
11/19/2010 Authors: Jagannath S; Vij R; Kaufman JL; Martin T; Niesvizky R; Gabrail NY; Alsina M; Wong AF; Le MH; McCulloch L -
Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients
Volume: 116 Page(s): 806 - 807
11/19/2010 Authors: Vij R; Kaufman JL; Jakubowiak AJ; Stewart AK; Jagannath S; Kukreti V; McDonagh KT; Alsina M; Bahlis NJ; Belch A -
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.
Transfusion Volume: 50 Page(s): 2424 - 2431
11/01/2010 Authors: Akhtari M; Giver CR; Ali Z; Flowers CR; Gleason CL; Hillyer CD; Kaufman J; Khoury HJ; Langston AA; Lechowicz MJ -
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD -
Melphalan or no melphalan: that is the question.
Oncology (Williston Park) Volume: 24 Page(s): 1000 - 1001
10/01/2010 Authors: Kaufman J; Lonial S -
Melphalan or No Melphalan: That Is the Question KAUFMAN ARTICLE REVIEWED
ONCOLOGY-NEW YORK Volume: 24 Page(s): 1000 - 1001
10/01/2010 Authors: Kaufman J; Lonial S -
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood Volume: 116 Page(s): 679 - 686
08/05/2010 Authors: Richardson PG; Weller E; Lonial S; Jakubowiak AJ; Jagannath S; Raje NS; Avigan DE; Xie W; Ghobrial IM; Schlossman RL -
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Cancer Volume: 116 Page(s): 3143 - 3151
07/01/2010 Authors: Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S -
RESULTS OF PX-171-004, AN ONGOING OPEN-LABEL, PHASE II STUDY OF CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (R/R MM) WITH OR WITHOUT PRIOR BORTEZOMIB EXPOSURE
Volume: 95 Page(s): 452 - 452
06/15/2010 Authors: Stewart K; Siegel D; Wang M; Kaufman J; Jakubowiak A; Jagannath S; Kukreti V; McDonagh K; Alsina M; Bahlis N -
ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
Volume: 95 Page(s): 157 - 158
06/15/2010 Authors: Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman J; Leleu X; Tsao C; Fry J -
ANTI-CD22 IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN (CMC-544) + RITUXIMAB: CLINICAL ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR 'AGGRESSIVE' LYMPHOMA
Volume: 95 Page(s): 238 - 238
06/15/2010 Authors: Verhoef G; Dang N; Smith M; Offner F; Johnson P; Rohatiner A; Kaufman J; Gine E; Coiffier B; Czuczman M -
ANTI-CD22 IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN (CMC-544) + RITUXIMAB: CLINICAL ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR 'AGGRESSIVE' LYMPHOMA
Volume: 95 Page(s): 238 - 238
06/01/2010 Authors: Verhoef G; Dang N; Smith M; Offner F; Johnson P; Rohatiner A; Kaufman J; Gine E; Coiffier B; Czuczman M -
RESULTS OF PX-171-004, AN ONGOING OPEN-LABEL, PHASE II STUDY OF CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (R/R MM) WITH OR WITHOUT PRIOR BORTEZOMIB EXPOSURE
Volume: 95 Page(s): 452 - 452
06/01/2010 Authors: Stewart K; Siegel D; Wang M; Kaufman J; Jakubowiak A; Jagannath S; Kukreti V; McDonagh K; Alsina M; Bahlis N -
ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
Volume: 95 Page(s): 157 - 158
06/01/2010 Authors: Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman J; Leleu X; Tsao C; Fry J -
Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM)
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Shah JJ; Cohen AD; Zonder JA; Kaufman JL; Burt SM; Freeman BB; Rush S; Ptaszynski AM; Orlowski RZ; Lonial S -
Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R M/M)
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Vij R; Siegel DS; Kaufman JL; Jakubowiak AJ; Stewart AK; Jagannath S; Kukreti V; Le MH; Bennett MK; Wang M -
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.
Volume: 114 Page(s): 1481 - 1481
11/20/2009 Authors: Lonial S; Francis D; Karanes C; Trudel S; Dollard AM; Aceo F; Gul E; Kakar S; Krishnan AY; Reece DE -
The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated
BLOOD Volume: 114 Page(s): 1432 - 1432
11/20/2009 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Lonial S; Flowers CR -
The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.
Volume: 114 Page(s): 673 - 673
11/20/2009 Authors: Deshpande SS; Lechowicz MJ; Sinha R; Kaufman JL; Boise LH; Lonial S; Flowers CR -
Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Volume: 114 Page(s): 1151 - 1152
11/20/2009 Authors: Muringampurath-John D; Flowers CR; Jabbar AA; Sinha R; Arellano M; Bernal-Mizrachi L; Kaufman JL; Jaye DL; Chen Z; Lechowicz MJ -
Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.
Volume: 114 Page(s): 1496 - 1496
11/20/2009 Authors: Nooka AK; Kaufman JL; Heffner LT; Gleason CL; Lonial S -
Updated Results of Bortezomib-Naive Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM)
Volume: 114 Page(s): 127 - 128
11/20/2009 Authors: Wang L; Siege D; Kaufman JL; Stewart AK; Jakubowiak AJ; Alsina M; Kukreti V; Bahlis NJ; McDonagh KT; Belch A -
PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
Volume: 114 Page(s): 128 - 128
11/20/2009 Authors: Siegel D; Wang L; Orlowski RZ; Kaufman JL; Stewart AK; Kukreti V; Alsina M; Jakubowiak AJ; Jagannath S; McDonagh KT -
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or 'Aggressive' Lymphoma
Volume: 114 Page(s): 242 - 243
11/20/2009 Authors: Dang NH; Smith MR; Offner F; Verhoef G; Johnson P; Rohatiner AZS; Kaufman JL; Gine E; Coiffier B; Czuczman MS -
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.
Sci Signal Volume: 2 Page(s): ra73
11/17/2009 Authors: Hitosugi T; Kang S; Vander Heiden MG; Chung T-W; Elf S; Lythgoe K; Dong S; Lonial S; Wang X; Chen GZ -
Tolerability profile of carfilzomib enables full-dose anti-tumor treatment for up to 12 months
Volume: 7 Page(s): 560 - 560
09/01/2009 Authors: Kaufman J; Wang M; Siegel D; Stewart AK; Jakubowiak A; Kukreti V; McDonagh K; Jagannath S; Alsina M; Vij R -
SAFETY AND CLINICAL ACTIVITY OF THE ANTI-CD22 IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN (CMC-544) IN COMBINATION WITH RITUXIMAB IN RECURRENT/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA
Volume: 94 Page(s): 165 - 165
06/07/2009 Authors: Johnson WM; Fayad LE; Coiffier B; Smith MD; Rohatiner A; Hess G; Kaufman JL; Verhoef G; Offner F; Hua S -
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
Blood Volume: 113 Page(s): 5720 - 5726
06/04/2009 Authors: DiPersio JF; Stadtmauer EA; Nademanee A; Micallef INM; Stiff PJ; Kaufman JL; Maziarz RT; Hosing C; Frehauf S; Horwitz M -
SAFETY AND CLINICAL ACTIVITY OF THE ANTI-CD22 IMMUNOCONJUGATE INOTUZUMAB OZOGAMICIN (CMC-544) IN COMBINATION WITH RITUXIMAB IN RECURRENT/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA
Volume: 94 Page(s): 165 - 165
06/01/2009 Authors: Johnson WM; Fayad LE; Coiffier B; Smith MD; Rohatiner A; Hess G; Kaufman JL; Verhoef G; Offner F; Hua S -
Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results
Volume: 27
05/20/2009 Authors: Flowers C; Sinha R; Kaufman J; Shenoy P; Lewis C; Bumpers K; Rogatko A -
Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.
J Clin Oncol Volume: 27 Page(s): 8577
05/20/2009 Authors: Flowers C; Sinha R; Kaufman J; Shenoy P; Lewis C; Bumpers K; Rogatko A -
A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma.
J Clin Oncol Volume: 27 Page(s): 8597
05/20/2009 Authors: Lonial S; Francis D; Karanes C; Trudel S; Dollard A; Harvey D; Kaufman J -
Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma.
J Clin Oncol Volume: 27 Page(s): 8593
05/20/2009 Authors: Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Teoh N; Wegener WA; Goldenberg DM -
A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed HodgkiM#8217;s lymphoma
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Thertulien R; Frankel A; Evens A; Kaufman J; Horwitz S; Assad A; Cardarelli P; Tian J; Zhang Z; MacDowall M -
A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed HodgkiM#8217;s lymphoma
Volume: 69
05/01/2009 Authors: Thertulien R; Frankel A; Evens A; Kaufman J; Horwitz S; Assad A; Cardarelli P; Tian J; Zhang Z; MacDowall M -
Treatment of multiple myeloma: whence truth over belief?
Oncology (Williston Park) Volume: 23 Page(s): 420 - 423
04/30/2009 Authors: Kaufman J; Lonial S -
Treatment of relapsed and refractory myeloma.
Curr Hematol Malig Rep Volume: 4 Page(s): 99 - 107
04/01/2009 Authors: Kaufman J; Gleason C; Lonial S -
Treatment of Multiple Myeloma: Whence Truth Over Belief? The Kaufman article reviewed
ONCOLOGY-NEW YORK Volume: 23 Page(s): 420 - 423
04/01/2009 Authors: Kaufman J; Lonial S -
EXTRACORPOREAL PHOTOPHERESIS THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSE IS ASSOCIATED WITH CONTENT OF DENDRITIC CELLS AND T-CELLS IN PERIPHERAL BLOOD AT INITIATION OF TREATMENT
Volume: 15 Page(s): 128 - 129
02/01/2009 Authors: Akhtari M; Giver CR; Renfroe HM; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL -
PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
Volume: 15 Page(s): 154 - 155
02/01/2009 Authors: Hutcherson DA; Surati M; Sanvidge K; Harvey D; Al-Baldawi RN; Langston A; Flowers C; Lonial S; Kaufman J; Lechowicz MJ -
A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S60 - S60
02/01/2009 Authors: Kaufman JL; Lonial S; Sinha R; Torre C; Langston AA; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT -
SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequen
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S127 - S127
02/01/2009 Authors: David E; Lonial S; Barwick B; Peng X; Kaufman J; Garlich J -
Imipramine Blue, a Tricyclic Compound and an Inhibitor of NADPH Oxidase Induces G(2)/M Cell-Cycle Arrest
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S126 - S126
02/01/2009 Authors: David E; Lonial S; Kaufman JL; Arbiser J -
The research mission in myeloma.
Leukemia Volume: 23 Page(s): 422 - 423
02/01/2009 Authors: Richardson PG; San-Miguel J; Lonial S; Reece D; Jakubowiak A; Hussein M; Jagannath S; Mitsiades CS; Raje N; Kaufman J -
The importance of complete response in outcomes in myeloma.
Cancer J Volume: 15 Page(s): 465 - 472
01/01/2009 Authors: Nooka A; Kaufman J; Lonial S -
A Randomized Phase I Trial of Melphalan plus Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
Volume: 112 Page(s): 1144 - 1145
11/16/2008 Authors: Lonial S; Kaufman J; Torre C; Langston A; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT; Waller EK -
A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
Volume: 112 Page(s): 1270 - 1270
11/16/2008 Authors: Lonial S; Francis D; Karanes C; Trudel S; Reece DE; Krishnan A; Buacharem M; Smith R; Zaman F; Gul E -
Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease
Volume: 112 Page(s): 432 - 432
11/16/2008 Authors: Giver CR; Akhtari M; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL; Vaughn ML -
Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
Volume: 112 Page(s): 1247 - 1247
11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R -
Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM).
Volume: 112 Page(s): 1264 - 1265
11/16/2008 Authors: Jakubowiak A; Richardson P; Zimmerman TM; Alsina M; Kaufman JL; Harvey C; Brozo C; Kendall T; McAllister A; Hideshima T -
First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma.
Volume: 112 Page(s): 1266 - 1267
11/16/2008 Authors: Kaufman J; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Home H; Teoh N; Leoni MJ; Wegener WA; Goldenberg DM -
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP -
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
Clin Cancer Res Volume: 14 Page(s): 5090 - 5098
08/15/2008 Authors: David E; Sinha R; Chen J; Sun S-Y; Kaufman JL; Lonial S -
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Leukemia Volume: 22 Page(s): 1280 - 1281
06/01/2008 Authors: Mazumder A; Kaufman J; Niesvizky R; Lonial S; Vesole D; Jagannath S -
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
Clin Lymphoma Myeloma Volume: 8 Page(s): 52 - 54
02/01/2008 Authors: Gladney SP; Lonial S; Kaufman JL -
Maintenance Therapy in Multiple Myeloma
Page(s): 91 - 98
01/01/2008 Authors: Kaufman JL; Mihelic R; Lonial S -
The effect of rituximab on mobilization with AMD3100 plus G-CSF in patients with relapsed or refractory NHL or HD
Volume: 110 Page(s): 568A - 568A
11/16/2007 Authors: Kaufman JL; Cook AM; Flowers C; Langston AA; Lonial S; Lechowicz MJ; Khoury HJ; Calandra G; Waller N -
A randomized phase I trial of Melphalan plus Bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
Volume: 110 Page(s): 288A - 289A
11/16/2007 Authors: Lonial S; Kaufman J; Langston A; Heffner LT; Torre C; Lechowicz MJ; Flowers C; McMillan S; Arnold M; Waller NK -
Combination of bortezomib with tipifarnib (R115777) induces synergistic myeloma cell apoptosis via down-regulation of HDAC6 and inhibition of aggresome formation
Volume: 110 Page(s): 455A - 455A
11/16/2007 Authors: David E; Schafer-Hales K; Marcus AI; Kaufman JL; Lonial S -
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
Volume: 110 Page(s): 1055A - 1055A
11/16/2007 Authors: Kaufman JL; Gleason C; Heffner L; Lonial S -
Impact of prior lenalidomide treatment on peripheral blood stem cell (PBSC) mobilization in untreated multiple myeloma (MM) patients
Volume: 110 Page(s): 1057A - 1057A
11/16/2007 Authors: Mazumder A; Kaufman J; Lonial S; Jagannath S; Vesole D -
A multiple myeloma research consortium (MMRC) Multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with Relapsed/Refractory multiple myeloma (MM): Updated results
Volume: 110 Page(s): 354A - 354A
11/16/2007 Authors: Jakubowiak A; Zimmerman T; Alsina M; Richardson P; Kaufman J; Kendall T; Brozo C; McAllister A; Leister C; Hideshima T -
Maintenance therapy in lymphoma.
Clin Lymphoma Myeloma Volume: 7 Page(s): 507 - 513
09/01/2007 Authors: Mihelic R; Kaufman J; Lonial S; Flowers C -
Bortezomib,thalidomide and dexamethasone as induction
Volume: 92 Page(s): 181 - 181
06/01/2007 Authors: Kaufman JL; Gleason C; Heffner LT; Langston AA; Waller EK; Lonial S -
Maintenance therapy in multiple myeloma.
Leukemia Volume: 21 Page(s): 1150 - 1157
06/01/2007 Authors: Mihelic R; Kaufman JL; Lonial S -
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Transfusion Volume: 47 Page(s): 629 - 635
04/01/2007 Authors: Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK -
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
Blood Volume: 109 Page(s): 2604 - 2606
03/15/2007 Authors: Chanan-Khan AA; Kaufman JL; Mehta J; Richardson PG; Miller KC; Lonial S; Munshi NC; Schlossman R; Tariman J; Singhal S -
A randomized phase I trial of melphalan plus bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
Volume: 13 Page(s): 56 - 56
02/01/2007 Authors: Lonial S; Kaufman J; Langston AA; Khoury HJ; Torre C; Lechowicz MJ; Flowers C; Waller EK -
Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
Volume: 108 Page(s): 554A - 554A
11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ -
Patients receiving patifermin in conjunction with melphalan 200 required fewer platelet transfusions: Analysis of a retrospective cohort study.
Volume: 108 Page(s): 407B - 407B
11/16/2006 Authors: Hutcherson DA; Langston A; Lin CH; Flowers C; Lechowicz MJ; Waller N; Sessions JK; Kaufman JL; Jean Khoury H; Lonial S -
Impact of revised international working group criteria on lymphoma patients undergoing autologous stem cell transplantation.
Volume: 108 Page(s): 873A - 873A
11/16/2006 Authors: Lucas AS; Flowers C; Langston A; Lonial S; Lechowicz MJ; Waller N; Kaufman JL; Jean Khoury H -
T cell reconstitution in first 200 days post transplantation predicts long term survival in allogeneic hematopoetic progenitor cell transplantation (HPCT).
Volume: 108 Page(s): 920A - 920A
11/16/2006 Authors: Vann L; Larks M; Flowers C; Lonial S; Kaufman J; Lechowicz MJ; Langston AA; Khoury J; Waller N -
Infliximab for the treatment of chronic graft versus host disease.
Volume: 108 Page(s): 818A - 818A
11/16/2006 Authors: Tolbert E; Waller N; Khoury HJ; Lechowicz MJ; Flowers C; Lonial S; Vann L; Langston A; Kaufman JL -
A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus G-CSF) on dendritic cell and T-Cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant.
Volume: 108 Page(s): 964A - 964A
11/16/2006 Authors: Lonial S; McMillan S; Torre C; Langston AA; Hamilton E; Cook A; Flowers C; Kaufman JL; Lechowicz MJ; Waller N -
Perifosine induces DR4/DR5 expression leading to apoptosis that can be enhanced with exogenous TRAIL, and blocked with strategies directed at DR4/DR5 inhibition.
Volume: 108 Page(s): 984A - 984A
11/16/2006 Authors: David E; Sinha R; Kaufman JL; Lonial S -
A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma.
J Clin Oncol Volume: 24 Page(s): 17550
06/20/2006 Authors: Kaufman JL; Waller EK; Torre C; McMillan S; Langston A; Flowers C; Lechowicz M; Tighiouart M; Lonial S -
Proteasome inhibition: novel therapy for multiple myeloma.
Onkologie Volume: 29 Page(s): 162 - 168
04/01/2006 Authors: Kaufman JL; Lonial S -
Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia
Volume: 12 Page(s): 69 - 70
02/01/2006 Authors: Arellano M; Flowers C; Waller E; Lonial S; Kaufman J; Winton E; Khoury H; Langston A -
Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors
Volume: 12 Page(s): 132 - 132
02/01/2006 Authors: Ninan MJ; Arellano M; Philip A; Langston A; Flowers CR; Lonial S; Kaufman J; Lechowicz M; Khoury JH; Roback J -
Novel treatment approaches for patients with multiple myeloma.
Clin Lymphoma Myeloma Volume: 6 Page(s): 281 - 288
01/01/2006 Authors: Sinha R; Kaufman JL; Lonial S -
The Richardson/Schlossman/Hideshima et al article reviewed
ONCOLOGY-NEW YORK Volume: 19 Page(s): 1792 - +
12/01/2005 Authors: Kaufman JL; Lonial S -
Combination of Akt/PKB inhibition (perifosine) and farnesyl transferase inhibition (tipifarnib) results in increased cell death in myeloma cells lines.
Volume: 106 Page(s): 450A - 450A
11/16/2005 Authors: Sinha R; David E; Zeilter E; Torre C; Kaufman JL; Lonial S -
Combination of farnesyl transferase inhibitor (Tipifarnib) with perifosine induces apoptosis through phos-PDK1 in human lymphoma and leukemia cell lines.
Volume: 106 Page(s): 428A - 429A
11/16/2005 Authors: David E; Sinha R; Torre C; Kaufman JL; Lonial S -
Enhanced levels of apoptosis by combination of farnesyl transferase inhibition (tipifarnib) and proteasome inhibition (bortezomib) in myeloma cell lines and primary myeloma cells and its mechanistic effects on Akt and caspase pathways.
Volume: 106 Page(s): 451A - 452A
11/16/2005 Authors: Kaufman JL; David E; Torre C; Sinha R; Lonial S -
Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma
Volume: 11 Page(s): 6 - 6
02/01/2005 Authors: Kaufman JL; Lonial S; Hicks M; Langston A; Flowers C; Lechowicz MJ; Khoury H; Waller EK -
Multiple myeloma: the role of transplant and novel treatment strategies.
Semin Oncol Volume: 31 Page(s): 99 - 105
04/01/2004 Authors: Kaufman J; Lonial S -
Multiple myeloma: The role of transplant and novel treatment strategies
Volume: 31 Page(s): 99 - 105
04/01/2004 Authors: Kaufman J; Lonial S -
IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA.
J Immunol Volume: 172 Page(s): 1699 - 1710
02/01/2004 Authors: Kaiser WJ; Kaufman JL; Offermann MK -
Bortezomib inhibits T cell proliferation.
Volume: 102 Page(s): 61B - 61B
11/16/2003 Authors: Kaufman JL; Waller EK; Torre C; Boswell MG; Lonial S -
ISG15 conjugation and release: A novel antiviral host response in endothelial cells.
Volume: 102 Page(s): 278A - 279A
11/16/2003 Authors: Kaufman JL; Kaiser WJ; Wilkinson KD; Hassel BA; Offermann MK -
ISG15 and ISG43 in endothelial cells in response to interferon a and dsRNA.
Volume: 100 Page(s): 76B - 76B
11/16/2002 Authors: Kaufman JL; Offermann MK